With Emerging Markets On Radar, AstraZeneca Close To Teaming Up With India's Intas For Sourcing Sterile And Oncology Drugs
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - AstraZeneca is days away from signing an agreement with India's Intas Pharmaceuticals for supplies of a large number of generic sterile and oncology products to be sold in emerging markets. The deal will likely cover as many as 45 products to be sold in nine markets, with the scope for expanding the range of products further
You may also be interested in...
With Plans For Public Offerings, Emcure, Intas Set To Join Big League Of Indian Pharma
Experts believe Emcure and Intas may be able to withstand the vagaries of India’s choppy financial market, having developed strong pedigrees of products and consistently growing their businesses.
As Pfizer Deal Speeds Up, Aurobindo Pairs Up With AstraZeneca For Branded Generics Play In Emerging Markets
India's Aurobindo Pharma is turning out to be a partner of choice for Big Pharma companies that intend to dig aggressively into emerging markets with a branded generics product portfolio.
As Pfizer Deal Speeds Up, Aurobindo Pairs Up With AstraZeneca For Branded Generics Play In Emerging Markets
India's Aurobindo Pharma is turning out to be a partner of choice for Big Pharma companies that intend to dig aggressively into emerging markets with a branded generics product portfolio.